Rafa Laboratories has received a potential $186 million contract from the Biomedical Advanced Research and Development Authority to develop an intramuscular formulation of tranexamic acid, or IM TXA, a potential treatment for uncontrolled bleeding. Join top government and industry experts at the Potomac Officers Club’s 2025 Healthcare Summit on Feb. 12 to explore the latest